Penumbra Inc Stock
€231.10
Your prediction
Penumbra Inc Stock
Pros and Cons of Penumbra Inc in the next few years
Pros
Cons
Performance of Penumbra Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Penumbra Inc | -1.030% | 3.136% | 12.260% | 29.399% | 2.773% | 40.663% | 29.722% |
Bio-Rad Labs Inc. A | -0.860% | -0.078% | 3.370% | -16.470% | -18.943% | -47.903% | -40.514% |
Neogen Corp. | -2.850% | 0.830% | 17.961% | -66.712% | -59.500% | - | - |
Haemonetics Corp. | -0.880% | -1.299% | -28.750% | -31.940% | -39.603% | -37.959% | -38.378% |
News

Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP

3 Mid-Cap Medical Stocks Outperforming the Market
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and

Penumbra Stock: Executives Sell Shares Amid Strong Growth
Several high-ranking executives at Penumbra Inc. have recently sold substantial amounts of company stock, with transactions beginning in early March 2025. Board member Arani Bose divested shares